Prognostic Value of Lactate Dehydrogenase in Patients with Hepatocellular Carcinoma: A Meta-Analysis

Table 2

Subgroups analysis of combined HR for OS in HCC patients.

Subgroups	NO. of studies	NO. of patients	Pooled HR	P-value	Heterogeneity
			(95% CI)		I^2 (%)	P-value	Model
Sample size
<100	4	248	2.11 (1.29-3.46)	0.003	57.2	0.071	random
≥100	5	2128	2.13 (1.61-2.81)	0.000	51.4	0.084	random
Region
Asian	6	2146	1.93 (1.60-2.32)	0.000	0	0.646	random
Caucasian	3	230	2.67 (1.11-6.44)	0.029	85.9	0.001	random
Cutoff value
≤200	2	720	2.70 (0.97-7.50)	0.057	62.8	0.101	random
200-400	4	721	2.00 (1.56-2.57)	0.000	0	0.710	random
≥400	3	935	2.12 (1.14-3.94)	0.018	84.2	0.002	random
Tumor stage type
BCLC	4	780	2.11 (1.40-3.17)	0.000	77.8	0.004	random
TNM	2	1426	1.82 (1.39-2.38)	0.000	0	0.754	random
Others	3	170	2.73 (1.53-4.89)	0.001	20.6	0.284	random
Therapy method
resection	3	1189	1.95 (1.44-2.06)	0.000	29.7	0.241	random
TACE	2	152	4.22 (2.53-7.04)	0.000	0	0.817	random
others	4	1035	1.61 (1.35-1.93)	0.000	0	0.392	random

Notes: HR: hazard ratio; 95% CI: 95% confidence intervals; OS: overall survival; NO: number; BCLC: Barcelona Clinic Liver Cancer; TNM: Tumor Node Metastasis; TACE: transcatheter arterial chemoembolization.